Journal of Oncology

The Role of Non-Coding RNA in the Regulation of Tumor Signaling Pathways

Publishing date
01 Jul 2022
Submission deadline
25 Feb 2022

Lead Editor
Guest Editors

1Nanjing Medical University, Nanjing, China

2NY State Institute for Basic Research in Developmental Disabilities, Staten Island, USA

3Ohio State University Wexner Medical Center, Columbus, USA

The Role of Non-Coding RNA in the Regulation of Tumor Signaling Pathways

Call for papers

This Issue is now open for submissions.

Papers are published upon acceptance, regardless of the Special Issue publication date.

 Submit to this Special Issue


Signaling pathways have been extensively studied for their varied roles in cancer development, and it is now clear that NF-κB also plays a major role in a large variety of human cancers, in particular cancers of immune cell origin. The combination of PI3K/AKT/mTOR inhibitors with radiation can increase the radiosensitivity of malignant cells by autophagy activation. STAT3 mediates key inflammatory mechanisms in colitis-associated cancer, becomes excessively activated in CRC, and enhances cancer cell proliferation, tumor growth, angiogenesis, invasion, and migration. Targeted therapy of various cancers is far from being well-understood and implemented in daily practice, and so there is an urgent need to understand cancer cells, from pathways to diagnosis and therapy.

Non-coding RNAs (ncRNAs) are a group of genes with limited or no protein-coding capacity. Based on their length, ncRNAs are divided into long noncoding RNAs (> 200 nucleotides) and small noncoding RNAs. Small noncoding RNAs can be divided into small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), microRNAs (miRNAs), and piwi-interacting RNAs (piRNAs). A large number of studies have found that ncRNAs play important roles in the physiological and pathological processes of various human diseases, including cancer.

The aim of this Special Issue is to gather papers that further our understanding of the role of ncRNAs in regulating cancer cell signaling pathways, from a molecular basis to malignant phenotypes. We welcome both original research and review articles.

Potential topics include but are not limited to the following:

  • Wnt/beta-catenin signaling pathway
  • STAT3 signaling pathway
  • p53 signaling pathway
  • NF-κB signaling pathway
  • PI3K/Akt signaling pathway
  • Hedgehog signaling pathway
  • Androgen/Androgen Receptor signaling pathway
Journal of Oncology
 Journal metrics
Acceptance rate24%
Submission to final decision66 days
Acceptance to publication37 days
Journal Citation Indicator0.680
Impact Factor4.375

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.